NCT06624228: An ongoing trial by UCB Biopharma SRL
This trial is ongoing. It must report results 10 months, 1 week from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06624228 |
|---|---|
| Title | A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 21, 2024 |
| Completion date | Feb. 6, 2026 |
| Required reporting date | Feb. 6, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |